| Old Articles: <Older 8721-8730 Newer> |
|---|
 |
Chemistry World
November 21, 2013
Jennifer Newton |
Barrie Rhodes: Open innovation Barrie Rhodes is the director of technology development at Aesica Pharmaceuticals in the UK. and has successfully introduced new technologies such as hot-melt extrusion and amide-bond formation technology.   |
Fast Company
Dec 2013/Jan 2014
Paul Watcher |
Making Senses Last December, IBM's VP of innovation predicted that computers would be able to mimic all five of the senses. Recent advances in perception technology actually make that halfdecade timeline look too conservative. |
Chemistry World
November 14, 2013
Phillip Broadwith |
Novartis sells off blood diagnostics division Swiss-based company Novartis has agreed to sell off its blood transfusion diagnostics unit to Spanish blood products specialist Grifols for $1.7 billion. |
Chemistry World
November 12, 2013
Dinsa Sachan |
Rough patch for India's clinical trial industry The Indian clinical trial industry is beset by uncertainty. Campaigners have petitioned the courts claiming that drug companies are exploiting poor people and this has led to more than 100 trials being put on hold. |
Information Today
November 12, 2013
Abby Clobridge |
A Conversation With BioMed Central's Cockerill on Open Access Publishing BMC was founded in 2000 and was acquired by Springer Science+Business Media in 2008. Last month, I had a chance to sit down with Matthew Cockerill to talk about some of his experiences with OA and STM publishing. |
Chemistry World
November 11, 2013
Phillip Broadwith |
Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. |
Chemistry World
November 11, 2013
Sarah Houlton |
Mis-selling lands J&J with $2.2bn fine Johnson & Johnson has been given a hefty fine in the US for mis-selling three drugs. The company, and its subsidiaries Janssen and Scios, will pay $2.2 billion. |
Pharmaceutical Executive
November 1, 2013 |
Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation. |
Pharmaceutical Executive
November 1, 2013
Timothy Denman |
Supply Chain: Scanning the Future The US and Europe are moving toward the enactment of new legislation that will change the way pharma products are handled and shipped throughout the supply chain. |
Pharmaceutical Executive
November 1, 2013
Ben Comer |
2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters. |
| <Older 8721-8730 Newer> Return to current articles. |
